Journal of Clinical Oncology
Articles in this Issue
Association between metastatic site and survival in non–small cell lung cancer: A SEER-based cohort study.
e20658 Background: The recently updated 9th edition TNM staging system is the most widely used prognostic tool for non-sma...
The evolving landscape of chimeric antigen receptor (CAR) T-cell therapy for plasma cell leukemia: A systematic review of early outcomes.
e19508 Background: Plasma cell leukemia (PCL) is an aggressive and rare manifestation of multiple myeloma with limited the...
SGLT-2 inhibitors: More than glycemic control in diabetic patients with renal cell carcinoma? A real-world multicenter retrospective study.
e16560 Background: Renal cell carcinoma (RCC) is the most common primary malignancy of the kidney, and Diabetes Mellitus (...
Potential and pragmatism: Clinical and public health implications of multi-cancer early detection (MCED) screening via cfDNA in asymptomatic adults.
e22570 Background: Blood-based multi-cancer early detection (MCED) tests analyze cfDNA biomarkers to screen for multiple c...
Factors associated with non-receipt of fertility counseling during cervical cancer treatment: Insights from the ACHIEVE study.
e17530 Background: The American Society of Clinical Oncology recommends that all individuals of reproductive age with canc...
Overall survival analysis of a heavily pretreated population of patients with bone sarcomas treated with mecbotamab vedotin, a conditionally binding ADC targeting AXL.
11511 Background: Patients with metastatic bone sarcomas continue to lack effective therapies. AXL, a cell-surface recepto...
A phase 2 multicenter, open-label, parallel cohort study to evaluate the efficacy, safety, and pharmacokinetic profile of ABN401 in patients with advanced solid tumors harboring c-MET dysregulation.
8641 Background: Vabametkib is a small-molecule, tyrosine kinase inhibitor (TKI) that is a highly selective type I inhibit...
Predictors of mortality in patients with HIV and tumor lysis syndrome.
e19038 Background: Patients with Human Immunodeficiency Virus (HIV) are at increased risk for developing cancer, and malig...
First-in-human study of AAV6-NeuroD1 trans-differentiation therapy in recurrent malignant glioma.
2012 Background: Recurrent glioblastoma (GBM) has a median survival of less than 9 months. NeuroD1 is a neural transcripti...
Beamion LUNG-3: Zongertinib in resectable <i>HER2</i> -mutant NSCLC.
TPS8129 Background: Zongertinib is an irreversible tyrosine kinase inhibitor that selectively inhibits HER2 while sparing...
Distinctive profile of antiproliferative activity and interaction with doxorubicin of a new indole alkaloid P1 from <i>Petasites hybridus</i> in molecularly diverse breast cancer cell lines.
e12581 Background: Despite the efficacy of anthracyclines in breast cancer (BC) treatment, their use is limited by cardiot...
Efficacy of chemotherapy after PARP inhibitor progression in ovarian cancer: A large real-world cohort.
e17592 Background: PARP inhibitors (PARPi) have revolutionized the treatment of ovarian cancer in the maintenance setting....
Circulating tumor DNA (ctDNA) tumor fraction (TF) dynamics to refine progression-free survival and radiographic response during anti-EGFR rechallenge in metastatic colorectal cancer.
3572 Background: Reliable biomarkers of benefit from anti-EGFR rechallenge are needed in anti-EGFR-refractory metastatic c...
International variation in diagnostic and treatment practices in patients with HER2+ EBC: The RWE PEARL-HER2 study.
517 Background: Pts with HER2+ EBC achieving pCR post neoadjuvant chemotherapy (NACT) with trastuzumab (H) and pertuzumab...
Contemporary real-world outcomes of mantle cell lymphoma in Colombia: Results from an expanded multicenter cohort.
e19077 Background: Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma with limited contemporary real-...
Insights from patients with early-stage, hormone positive breast cancer (BC) using an artificial intelligence (AI)–driven digital navigation platform.
e12554 Background: Patients with BC navigate complex treatment decisions influenced by tumor biology, disease extent, and...
Intravenous oncolytic virus IDOV-Safe in pMMR/MSS metastatic colorectal cancer.
3536 Background: Proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC) is largel...
Additional health-related quality of life (HRQoL) analysis from DESTINY-Gastric04 (DG-04), a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) unresectable/metastatic gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA).
4111 Background: In DG-04 (NCT04704934), a statistically significant and clinically meaningful improvement in overall surv...
Clinical and metabolic predictors of complete response after neoadjuvant immune checkpoint blockade in resectable gastroesophageal adenocarcinoma (GEC).
e16149 Background: Perioperative durvalumab + FLOT improves overall survival and is a new treatment option for patients wi...
Failure to rescue following colorectal cancer surgery at minority-serving hospitals: A National Inpatient Sample analysis.
e23067 Background: Given persistent disparities in surgical outcomes, this study examines patient- and system-level factor...
Single-institution clinical outcomes with pembrolizumab plus neoadjuvant radiation (SARC032 regimen) with or without neoadjuvant doxorubicin/ifosfamide in high grade soft tissue sarcomas.
e23552 Background: SARC032 therapy (pembrolizumab plus neoadjuvant XRT, PD-1 + XRT) represents an appealing perioperative...
FOLFOXIRI/bevacizumab in microsatellite stable (pMMR/MSS) <i>RAS</i> and <i>BRAF</i> wild-type “gene-altered” metastatic colorectal cancer (mCRC): The HYPERTRIBE study.
3560 Background: Negative hyperselection may allow patient refinement for the use of anti-EGFRs in chemo-naïve pMMR/MSS,...
Structural determinants of cancer risk: Healthcare violence, mental health, and cancer-related risk behaviors among transgender individuals in Brazil.
e13728 Background: Transgender and gender-diverse populations experience disproportionate exposure to healthcare-related v...
BXCL701 plus pembrolizumab in second-line advanced pancreatic ductal adenocarcinoma: Final outcomes of the EXPEL PANC trial.
4201 Background: Pancreatic ductal adenocarcinoma (PDAC) is resistant to immune checkpoint inhibitors, in part due to a co...
Comparative effectiveness of ALK tyrosine kinase inhibitors in ALK-positive non–small cell lung cancer: A systematic review and network meta-analysis.
e20753 Background: Next generation ALK tyrosine kinase inhibitors (TKIs) have transformed ALK positive advanced non-small...